Avillion, a drug development company focused on the co-development and financing of late-stage pharmaceutical candidates, has appointed Kathryn Gregory chief business officer. She joins Avillion from Seneb BioSciences, an early-stage, rare disease company. During her career, Kathryn has worked in senior roles in pharmaceutical and biotechnology companies including Purdue Pharma where she was responsible for business development transactions, identification, evaluation and negotiation of new business development opportunities and collaborations. Prior to Purdue, she y was at Shire Pharmaceuticals and was responsible for business development transactions for the Neuroscience and Ophthalmology Business Units.